Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

faldaprevir

- PMLiVE

Novartis gets EU approval for multiple sclerosis therapy Mayzent

Offers subgroup of patients an important new treatment option

- PMLiVE

AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

Outperformed rival across all primary and secondary endpoints

- PMLiVE

Novartis links up with NHS for speedy access to cholesterol drug inclisiran

Collaboration will see drug offered to patients across the UK via clinical study

- PMLiVE

Boehringer bolsters NASH pipeline with Enleofen link-up

Agrees to pay up to €1bn for each new marketed product

- PMLiVE

Novartis reveals positive efficacy data for Xolair follow-up

Next-generation treatment is more effective than current therapy

- PMLiVE

Novartis picks up inclisiran after completion of MedCo acquisition

If approved could become blockbuster cholesterol treatment

- PMLiVE

Boehringer Ingelheim to manufacture first biologic in China under new reforms

German pharma will manufacture BeiGene's PD-1 inhibitor

Roche Basel Switzerland

EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

Could face tough competition soon from a number of rivals

- PMLiVE

Gilead’s NASH hopes crushed as candidates fail again

Monotherapy and combination regimens produced disappointing results

- PMLiVE

Novartis ditches oral asthma drug after disappointing phase 3 readout

Bad news for Gossamer’s would-be rival DP2 antagonist

- PMLiVE

Intec battered as Novartis ducks out of Accordion collaboration

Shares fell by more than 12% after the annoucement

- PMLiVE

Novartis strengthens case for its combination asthma drug

Demonstrated significant benefits in uncontrolled asthma patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links